C
Christian Beck
Researcher at Heidelberg University
Publications - 11
Citations - 160
Christian Beck is an academic researcher from Heidelberg University. The author has contributed to research in topics: Transplantation & Buffy coat. The author has an hindex of 7, co-authored 11 publications receiving 158 citations.
Papers
More filters
Journal ArticleDOI
Establishment and optimization of a flow cytometric method for evaluation of viability of CD34+ cells after cryopreservation and comparison with trypan blue exclusion staining
TL;DR: This data indicates that trypan blue exclusion staining is probably the most frequently applied method for assessment of viability in peripheral blood progenitor cell grafts after cryopreservation.
Journal ArticleDOI
A novel method for simultaneous analysis of specific platelet antibodies: SASPA.
TL;DR: Improved method based on simultaneous detection of various platelet‐specific immunoglobulin G (IgG) and IgM antibodies that proved to be a rapid and reliable assay that required less platelets than other methods.
Journal ArticleDOI
Engraftment capacity of umbilical cord blood cells processed by either whole blood preparation or filtration
TL;DR: It seems very probable that filter‐processed UCB transplants will also result in sufficient hematopoietic reconstitution in humans, as the data of NOD/SCID mice transplantation demonstrated a significant engraftment capacity of HPCs processed by filtration.
Journal ArticleDOI
Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients.
Anders Österborg,William G. Wierda,Jiřà Mayer,Georg Hess,Peter Hillmen,Johannes Schetelig,Anna Schuh,Lukã¡å¡ Smolej,Christian Beck,Brigitte Dreyfus,Andrzej Hellman,Piotr B. Kozlowski,Michael Pfreundschuh,Rita Rizzi,Martin Spacek,Jennifer Phillips,Ira Gupta,Vanessa C. Williams,Roxanne C. Jewell,Noelia Nebot,Steen Lisby,Martin J. S. Dyer +21 more
TL;DR: Retreatment and maintenance therapy was feasible in patients with heavily pretreated CLL and appeared to result in more durable disease control than initial ofatumumab treatment in this subset of patients who may have a more favourable disease profile.
Journal ArticleDOI
Myelodysplastic syndrome of donor origin subsequent to successful treatment of myeloid/NK-cell precursor leukaemia with allogeneic PBSCT : two very rare conditions in one patient
TL;DR: It is concluded that allogeneic PBSCT is a therapeutic option for patients with myeloid/NK-cell precursor acute leukaemia, a very rare malignant disease, despite the fatal outcome due to infection.